1) Neurology® Neuroimmunology & Neuroinflammation: Therapy with natalizumab is associated with high JCV sero-conversion and rising JCV index values 2) What's Trending: Interviews with Sandi Moriarity and Andy Lucas about their positions and responsibilities with the Neurology podcasts3) Topic of the month: Pediatric multiple sclerosis This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Melanie Ward interviews Dr. Nicholas Schwab about his Neurology: Neuroimmunology & Neuroinflammation paper on therapy with natalizumab and how it is associated with high JCV sero-conversion and rising JCV index values. Dr. Ted Burns is interviewing Sandi Moriarity and Andy Lucas for our "What's Trending" feature of the week about their positions and responsibilities with the Neurology podcast. In the next part of the podcast Dr. Ruth Ann Marrie interviews Dr. Brenda Banwell about the topic of diagnosis of pediatric multiple sclerosis and acute disseminated encephalomyelitis.DISCLOSURES: Dr. Schwab received funding for travel expenses from Biogen Idec; received speaking honoraria from Novartis; has a patent for Usage of L-selectin as predictive marker for progressive multifocal leukoencephalopathy; and receives research support from the Deutsche Forschungsgemeinschaft German Research Foundation and University Münster, IMF.Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Sandi Moriarity is Senior Production Editor, Neurology.Andy Lucas is Audio-Visual Administrator, American Academy of Neurology.Dr. Marrie serves as an editorial board member of Neurology and Multiple Sclerosis Journal; receives research support for clinical trials from Sanofi-Aventis, from the Canadian Institutes of Health Research, Research Manitoba, from Multiple Sclerosis Society of Canada and the National Multiple Sclerosis Society, from Multiple Sclerosis Scientific Foundation and from Consortium of Multiple Sclerosis Centers; received research support from the Public Health Agency of Canada.Dr. Banwell serves as an editorial board member of Neurology and Multiple Sclerosis and Related Disorders; serves on the scientific advisory board for Biogen Idec, Sanofi-aventis, Eli Lilly and Company, Novartis; served as a consultant to Biogen Idec, Eli Lilly and Company, Sanofi-aventis; spoken at an event supported by the Consortium of MS Centers; receives research support from the Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Research Foundation, and the National Multiple Sclerosis Society.NO CME WILL BE OFFERED THIS WEEK.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.